Please assess the completion status of the following clinical trial:

Trial Title: Escitalopram in Bipolar Depression: a Placebo-controlled Study of Acute and Maintenance Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with bipolar disorder in major depressive episode according to DSM-IV~* MADRS score of at least 20 points at screening and baseline~* 18-70 years of age~* Unchanged dose of mood stabilising medication for at least six weeks prior to inclusion~* Voluntary, informed and written consent~Exclusion Criteria:~* Non-affective psychotic symptoms at screening~* Pregnancy or breast-feeding~* Fertile women without appropriate contraception (the pill, IUD, or contraceptive injection)~* Substance dependence during the last three months prior to baseline~* Mental retardation and organic brain disorders~* Suicide risk that mandates specific measures~* Novel (within three months) or unstable medical conditions~* Clinically significant abnormal results on medical examination or blood samples~* Exposure to escitalopram during the last three months~* Allergic reactions to citalopram or escitalopram~* Anorexia nervosa with body mass index below 18~* Formal psychotherapy started within six weeks of screening~* Electroconvulsive therapy (ECT) during the current episode of depression~* Patients who are unlikely to be reliable and compliant with study procedures~* Patients who are not fluent in Norwegian

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).